Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • dinepat203 dinepat203 Feb 12, 2013 9:01 AM Flag

    PFIZER has offered $15 AMARIN ...How far 23M shorts in trouble !!

    Pfizer “alledgely” offered $15 cash for Amarin back in mid-2011.

    Many rumors here and there about who will eventually buyout Amarin because of its immensely lucrative Vascepa heart drug. But recent activities conclude me to say confidently that Pfizer will be the ultimate acquirer of Amarin. Here is why:

    Amarin patent 12/888994 had a recent update on September 10, 2012 to its application. This patent is for their combo statin-Vascepa study.

    see the full Vascepa filing

    It is finally known that this update posted on September 10th shows that Amarin has clearly picked atorvastatin (Lipitor) as their statin they will use in their combo study. Lipitor is owned by Pfizer.
    As seen on the thumbnail on the left, “the Office Action states that Applicant is required to elect a species of statin and a species of omega-3 fatty acid. Applicant elects atorvastatin as the statin species, and ethyl eicosapentaenoate as the omega-3 fatty acid species.”

    Amarin management has been in talks with Pfizer about this combo statin study and will only choose a partner who will be bringing (BUYOUT) or helping (PARTNERING) them to market.

    This shows that Pfizer was serious in the past about acquiring Amarin. It was a low-ball offer as Amarin had no existing patent portfolio to defend Vascepa from generics. But now Amarin’s patent fortress is up and getting stronger by the month. Pfizer or any big pharma can now entertain a buyout more seriously.

    Pfizer in August 2012 applies for trademarks for a drug that has the exact same details of Vascepa.
    The “mystery” Pfizer drug has a description of being a cardiovascular prescription drug that can also be used for additional inflammatory-related health indications, including diabetes and cardiovascular events. Several pending names suggest “natural or nature identical” type active ingredient which in my opinion is icosapent ethyl, the active ingredient in Vascepa.
    Pfizer, with its Lipitor being off patent in May 2012, needs to find something immediately to replenish the lost revenue stream the Lipitor generics will take from it.
    Vascepa is the likely candidate among all current newly developed drugs that can do just those Lipitor-like number$.

    So the question is … WHEN will Pfizer make their bid public
    Or when will Amarin management share with us the details of the Pfizer buyout price negotiations

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think that the "heard mentality" of assuming Pfizer MUST be the suitor because Amarin chose Atovastorin (lipitor) vs say AZ's Crestor may be dangerous.

      I'd suggest leaving a space in you mind that the choice was because Atovastorin is now considered to be more effective:

      htt*://*ww.forbes.co*/sites/larryhusten/2011/09/02/rosuvastatin-fails-to-best-atorvastatin-in-ivus-study-of-atherosclerosis-progression/

      I guess we'll see how this plays out.

    • Irish law requires any formal offer be announced publicly.

      Sentiment: Hold

    • Makes sense. This is what happens when greed kicks in. Instead of $15 we are stuck with $8 and no catalysts that could move the stock up. Right now the only thing that could move this back up near that level is sales, and don't hold your breath for great sales numbers anytime soon.

      The next move for PFE will be to offer $12.

      This is how these small companies get taught lessons. Don't be greedy. In the end, it will cost you.

    • Pfizer should declare this

      • 1 Reply to dinepat203
      • There are many reasons not to declare it, one of which is they are negotiating the acquisition of AMRN. Last thing you want to do is drive the market cap up in the middle of the negotiation. My guess is they (and other potential suitors) have asked AMRN to go quiet about offers during the negotiation process. I think GSK is one of the other potential suitors. They have taken down their Lovaza website during the Vascepa launch as a supportive gesture. It's like saying, "to show you how serious we are about Vascepa we're going to take marketing of the competitive drug offline during your launch."

 
AMRN
2.35+0.06(+2.62%)Sep 4 4:00 PMEDT